International Journal of Pharmacology and Pharmaceutical Research 2024; 6(2): 20-26

International Journal of Pharmacology and Pharmaceutical Research

ISSN Print: 2664-7184
ISSN Online: 2664-7192
IJPPR 2024; 6(2): 20-26
www.pharmacologyjournals.com
Received: 28-05-2024
Accepted: 13-07-2024

Riya
Assistant Professor,
Department of Pharmacology,
Rama and Krishana College of
Pharmacy, Narnaul,
Mahendragarh, Haryana,
India

Priyanka
Assistant Professor,
Department of Pharmacology.,
Rama and Krishana College of
Pharmacy, Narnaul,
Mahendragarh, Haryana,
India

Dr. Atul Kumar
Principal, Department of
Pharmaceutics, Rama and
Krishna College of Pharmacy,
Narnaul, Mahendragarh,
Haryana, India

Corresponding Author:
Riya
Assistant Professor,
Department of Pharmacology,
Rama and Krishana College of
Pharmacy, Narnaul,
Mahendragarh, Haryana,
India

Therapeutic targeting of TNF-α and IL-17 in psoriasis: Mechanisms of action and clinical efficacy of biologic agents

Riya, Priyanka and Atul Kumar

DOI: https://dx.doi.org/10.33545/26647184.2024.v6.i2a.37

Abstract
Psoriasis is a chronic, immune-mediated inflammatory skin disorder that significantly affects patients' quality of life. It is characterized by the hyperproliferation of keratinocytes and a dysregulated immune response, with systemic inflammation playing a central role in disease progression. Tumor necrosis factor-alpha (TNF-α) and interleukin-17 (IL-17) are two crucial cytokines that drive the inflammatory pathways in psoriasis, making them prime targets for therapeutic intervention. The development of biologic agents that selectively inhibit TNF-α and IL-17 has transformed the treatment landscape, providing new hope for patients with moderate to severe forms of the disease. These biologics offer a significant advantage over conventional therapies, demonstrating superior efficacy, faster onset of action, and a better safety profile in clinical trials. This paper presents a comprehensive review of the pathophysiological roles of TNF-α and IL-17 in psoriasis and the mechanisms by which biologic agents targeting these cytokines mitigate disease symptoms. Furthermore, it discusses the clinical efficacy of these agents, focusing on pivotal trials that have established their place in psoriasis management. The review also examines long-term outcomes and the potential for sustained disease remission, as well as safety concerns, including the risk of infections and adverse effects associated with these therapies. In addition, the paper explores future directions for biologic treatments in psoriasis, including emerging therapies and strategies for optimizing long-term disease control. Through this review, we aim to provide insight into the evolving therapeutic approaches for psoriasis and their impact on patient outcomes.

Keywords: Psoriasis, TNF-α, IL-17, biologic agents, immune modulation, clinical efficacy, disease remission, safety

1. Introduction
Psoriasis is a chronic, immune-mediated disorder that impacts approximately 2-3% of the global population, with a higher prevalence observed in countries with colder climates. It is a multifactorial disease characterized by the abnormal proliferation of keratinocytes and an exaggerated immune response that leads to the formation of well-demarcated, red, scaly plaques on the skin. In a subset of patients, psoriasis is accompanied by psoriatic arthritis (PsA), a condition that results in joint inflammation, pain, and eventual joint damage if left untreated. Psoriasis is more than just a skin disorder; it is associated with multiple comorbidities, including cardiovascular diseases, metabolic syndrome, and psychological disorders such as depression and anxiety, all of which add to the disease burden.

The pathogenesis of psoriasis is primarily driven by dysregulated immune pathways, specifically involving T-helper (Th) cells. The aberrant activation of Th1 and Th17 cells leads to the overproduction of key pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-17 (IL-17), interleukin-23 (IL-23), and interferon-gamma (IFN-γ). These cytokines, in turn, promote the activation and recruitment of immune cells to the skin, triggering the inflammatory cascade that culminates in the hallmark psoriatic lesions. Among these cytokines, TNF-α and IL-17 have emerged as pivotal mediators of disease progression, playing crucial roles in the amplification of inflammation and keratinocyte hyperproliferation.

Historically, the treatment of psoriasis has included topical therapies, phototherapy, and systemic agents such as methotrexate, cyclosporine, and retinoids.

While these treatments have shown efficacy in controlling mild to moderate forms of the disease, they are often associated with significant side effects and suboptimal long-term outcomes in patients with moderate to severe psoriasis. In the past two decades, the development of biologic agents targeting specific immune pathways has revolutionized the management of psoriasis. Biologic therapies that inhibit TNF-α and IL-17 have demonstrated superior efficacy and a more favorable safety profile compared to conventional systemic treatments.

TNF-α, a pro-inflammatory cytokine produced by macrophages, dendritic cells, and keratinocytes, plays a central role in the pathophysiology of psoriasis by promoting the recruitment of immune cells to the skin and enhancing the production of other inflammatory cytokines. TNF-α is also involved in promoting the hyperproliferation of keratinocytes, a hallmark feature of psoriatic lesions. The introduction of TNF-α inhibitors, such as infliximab, etanercept, and adalimumab, marked a significant advancement in psoriasis treatment, offering substantial reductions in disease severity and improving patient quality of life. Clinical trials have shown that these agents can achieve Psoriasis Area and Severity Index (PASI) 75 responses in a majority of patients, with sustained improvements over time.

IL-17, primarily produced by Th17 cells, is another key cytokine that drives psoriatic inflammation. IL-17 acts directly on keratinocytes, inducing the production of pro-inflammatory mediators such as chemokines and antimicrobial peptides, which further exacerbate the inflammatory response and contribute to the formation of psoriatic plaques. IL-17 inhibitors, including secukinumab, ixekizumab, and brodalumab, have been shown to be highly effective in treating moderate to severe psoriasis, with a significant proportion of patients achieving complete or nearly complete skin clearance (PASI 100) in clinical trials. These agents have set a new benchmark in psoriasis management by offering rapid onset of action and durable responses with a relatively low risk of serious adverse effects.

This paper aims to explore the molecular mechanisms of TNF-α and IL-17 inhibitors in the context of psoriasis, providing a detailed review of their efficacy and safety profiles. We will also discuss the clinical outcomes associated with these biologics, focusing on long-term disease remission, patient adherence, and quality of life improvements. Additionally, this paper will highlight ongoing challenges in psoriasis management, including the risk of secondary infections and the potential development of drug resistance, and will provide insights into the future of biologic therapy in this chronic condition.

2. Pathophysiology of psoriasis

Psoriasis is a complex, chronic autoimmune condition that primarily affects the skin but is increasingly recognized as a systemic disease due to its associated comorbidities, such as psoriatic arthritis, cardiovascular disease, and metabolic syndrome. The underlying pathology of psoriasis is driven by an intricate interaction between the immune system and keratinocytes, with both innate and adaptive immune responses playing crucial roles. At the heart of this pathogenesis is the dysregulation of T-helper (Th) cell responses, particularly Th1 and Th17 cells, which leads to the overproduction of pro-inflammatory cytokines that drive the characteristic hyperproliferation of keratinocytes and chronic inflammation observed in psoriatic plaques.

The immune system in psoriasis is abnormally activated, with the disease being initiated by environmental triggers, such as infections, stress, or skin trauma (Koebner phenomenon), in genetically susceptible individuals. These triggers lead to the activation of dendritic cells in the skin, which in turn activate T-cells, particularly Th1 and Th17 subsets. Th1 cells are primarily involved in the production of interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α), both of which are essential mediators of the inflammatory response in psoriasis. Th17 cells, on the other hand, secrete interleukin-17 (IL-17), a key cytokine that plays a direct role in driving keratinocyte hyperproliferation and amplifying the inflammatory response.

2.1 Role of TNF-α in Psoriasis

TNF-α is a pro-inflammatory cytokine that is produced by several cell types, including activated macrophages, dendritic cells, T-cells, and keratinocytes. It is one of the most important cytokines in the pathogenesis of psoriasis due to its ability to orchestrate various inflammatory responses. TNF-α acts by binding to its receptors, TNF receptor-1 (TNFR1) and TNF receptor-2 (TNFR2), which are expressed on the surface of immune cells and keratinocytes. Once bound, TNF-α triggers a cascade of intracellular signaling pathways, including the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and mitogen-activated protein kinase (MAPK) pathways, both of which are critical for the transcription of pro-inflammatory genes.

In psoriasis, TNF-α promotes the recruitment and activation of immune cells, such as neutrophils, dendritic cells, and T-cells, into the skin. It also stimulates keratinocytes to produce more cytokines and chemokines, perpetuating the inflammatory cycle. Importantly, TNF-α enhances the expression of adhesion molecules on endothelial cells, which facilitates the migration of immune cells from the bloodstream into the skin. This influx of immune cells leads to the characteristic erythematous, scaly plaques seen in psoriasis. Elevated levels of TNF-α have been detected in both the serum and lesional skin of psoriasis patients, further underscoring its central role in disease pathophysiology.

2.2 Role of IL-17 in Psoriasis

IL-17, particularly IL-17A, is another key cytokine involved in the pathogenesis of psoriasis. It is predominantly secreted by Th17 cells, but other immune cells, such as γδ T cells, innate lymphoid cells (ILCs), and neutrophils, can also produce IL-17. The production of IL-17 is driven by interleukin-23 (IL-23), which is secreted by dendritic cells in response to environmental triggers. IL-17A acts directly on keratinocytes, inducing them to produce pro-inflammatory mediators such as IL-6, CXCL1, and CCL20, as well as antimicrobial peptides like β-defensins and S100 proteins. These mediators further amplify the inflammatory response and contribute to the recruitment of neutrophils and other immune cells to the skin, leading to the development of psoriatic plaques.

One of the key features of IL-17 in psoriasis is its ability to promote keratinocyte proliferation and survival, contributing to the thickened epidermis (acanthosis) that is characteristic of the disease. IL-17 also induces keratinocytes to produce enzymes such as matrix metalloproteinases (MMPs), which degrade the extracellular matrix and further disrupt the normal skin architecture. This disruption, combined with the persistent inflammatory response, leads to the chronic nature of psoriasis.

IL-17 is considered a master cytokine in the Th17 pathway, and its importance in psoriasis has been highlighted by the success of IL-17-targeting biologic therapies. Elevated levels of IL-17 have been found in psoriatic lesions, and blocking IL-17 has been shown to rapidly reduce skin inflammation and keratinocyte hyperproliferation, leading to clinical improvement in patients with moderate to severe psoriasis.

2.3 Interaction Between TNF-α and IL-17 Pathways

While TNF-α and IL-17 have distinct roles in the pathogenesis of psoriasis, their pathways are highly interconnected, and their combined effects contribute to the maintenance of chronic inflammation in the skin. TNF-α has been shown to enhance the production of IL-17 by Th17 cells, creating a feed-forward loop that sustains the inflammatory environment in psoriatic skin. In addition, both TNF-α and IL-17 can synergistically induce the production of other pro-inflammatory cytokines and chemokines, further amplifying the immune response.

This interplay between TNF-α and IL-17 is a key reason why biologic agents that target these cytokines have been so successful in treating psoriasis. By inhibiting TNF-α or IL-17, these therapies effectively disrupt the inflammatory cascade at multiple levels, leading to a reduction in keratinocyte proliferation, immune cell infiltration, and overall inflammation. The combination of TNF-α and IL-17 inhibitors has been proposed as a potential therapeutic strategy, although this approach requires further investigation due to concerns about increased risks of infections and other adverse effects.

2.4 Role of Other Cytokines and Immune Cells in Psoriasis

In addition to TNF-α and IL-17, other cytokines and immune cells play important roles in the pathogenesis of psoriasis. IL-23, produced by dendritic cells, is a key driver of the Th17 response and promotes the production of IL-17. Blocking IL-23 has also been shown to be effective in treating psoriasis, highlighting the central role of the IL-23/Th17 axis in disease development.

Keratinocytes, the primary cell type in the epidermis, are both targets and active participants in the psoriatic inflammatory process. In response to cytokines like TNF-α and IL-17, keratinocytes produce a wide range of inflammatory mediators, including chemokines (e.g., CXCL8, which recruits neutrophils) and antimicrobial peptides (e.g., LL-37), which further exacerbate the immune response. Moreover, keratinocytes themselves can present antigens and activate T-cells, thereby contributing to the initiation and perpetuation of the immune response in psoriasis.

Other immune cells, such as neutrophils, macrophages, and mast cells, are also involved in psoriasis. Neutrophils are recruited to the skin by IL-17-induced chemokines and are found in the epidermis and dermis of psoriatic lesions, contributing to the formation of microabscesses (Munro's microabscesses) that are characteristic of the disease. Macrophages and mast cells also contribute to the production of pro-inflammatory cytokines and tissue remodeling enzymes, which further perpetuate the inflammatory process.

2.5 Implications for Therapeutic Targeting

The identification of TNF-α and IL-17 as key drivers of psoriasis has led to the development of biologic therapies that specifically target these cytokines, resulting in significant advances in the treatment of moderate to severe psoriasis. TNF-α inhibitors, such as infliximab, etanercept, and adalimumab, have been used for over a decade with demonstrated efficacy in reducing the severity of psoriasis and improving patients' quality of life. More recently, IL-17 inhibitors, such as secukinumab, ixekizumab, and brodalumab, have emerged as highly effective treatments, offering rapid and sustained clinical responses in patients with more refractory disease.

The success of these therapies underscores the importance of understanding the underlying immunological mechanisms driving psoriasis. By targeting specific cytokines like TNF-α and IL-17, biologic therapies can disrupt the pathogenic processes that lead to chronic inflammation and keratinocyte hyperproliferation. However, despite the efficacy of these treatments, challenges remain, particularly in terms of long-term safety, potential loss of efficacy over time (secondary failure), and the high cost of biologic agents.

In conclusion, the pathophysiology of psoriasis is driven by complex interactions between immune cells and keratinocytes, with TNF-α and IL-17 playing central roles in the initiation and maintenance of the disease. Targeting these cytokines has revolutionized psoriasis treatment, offering patients improved outcomes and a better quality of life. However, continued research is necessary to refine these therapies and develop new approaches that further improve the management of this chronic and debilitating disease.

3. TNF-α AND IL-17 IN PSORIASIS: MECHANISMS OF ACTION

The pathophysiology of psoriasis is primarily driven by the dysregulation of pro-inflammatory cytokines, among which tumor necrosis factor-alpha (TNF-α) and interleukin-17 (IL-17) play pivotal roles. These cytokines are critical mediators of the inflammatory cascade that results in keratinocyte hyperproliferation, increased immune cell infiltration, and the formation of psoriatic plaques. The advent of biologic therapies targeting TNF-α and IL-17 has provided highly effective treatment options for moderate to severe psoriasis, offering enhanced efficacy, safety, and convenience over conventional systemic therapies.

3.1 TNF-α Inhibition

TNF-α is one of the most important cytokines in the inflammatory response, particularly in autoimmune diseases such as psoriasis. It is produced by multiple immune cells, including macrophages, dendritic cells, and keratinocytes. Once secreted, TNF-α binds to TNF receptors on the surface of target cells, primarily TNFR1 and TNFR2, initiating a cascade of downstream signaling events. The binding of TNF-α to its receptors activates several pro-inflammatory signaling pathways, including the nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) pathways. These pathways lead to the transcription and production of other pro-inflammatory cytokines, such as

interleukin-1 (IL-1), interleukin-6 (IL-6), and interleukin-8 (IL-8), which further propagate the inflammatory response.
TNF-α is also involved in increasing the expression of adhesion molecules on endothelial cells, facilitating the migration of immune cells into the skin. In psoriasis, TNF-α promotes the recruitment of neutrophils and macrophages, contributing to the chronic inflammation characteristic of the disease. Moreover, TNF-α plays a direct role in enhancing keratinocyte proliferation and survival, which leads to the thickening of the epidermis and the formation of psoriatic plaques.
Biologic therapies that inhibit TNF-α have been developed to neutralize the cytokine's pro-inflammatory effects, thereby reducing the immune response and ameliorating the clinical manifestations of psoriasis. TNF-α inhibitors, including infliximab, etanercept, and adalimumab, have been shown to provide rapid and sustained reductions in disease severity. These biologics work by either binding to TNF-α directly or blocking its interaction with TNF receptors, thus preventing the cytokine from exerting its pathogenic effects.

3.2 IL-17 Inhibition
IL-17, particularly IL-17A, is a central effector cytokine in psoriasis. It is produced primarily by Th17 cells but is also secreted by other immune cells such as innate lymphoid cells (ILCs) and neutrophils. The production of IL-17A is induced by interleukin-23 (IL-23), another cytokine involved in the pathogenesis of psoriasis. IL-17A acts directly on keratinocytes, stimulating them to produce pro-inflammatory mediators such as chemokines (e.g., CXCL1, CXCL2, CXCL8), antimicrobial peptides (e.g., β-defensins, S100 proteins), and other cytokines (e.g., IL-6, IL-8).
The primary role of IL-17 in psoriasis is to drive keratinocyte hyperproliferation, which leads to the characteristic thickened, scaly plaques. IL-17 also enhances the recruitment of neutrophils to the skin, contributing to the formation of microabscesses in psoriatic lesions. In addition, IL-17 stimulates the production of matrix metalloproteinases (MMPs), which degrade extracellular matrix components and contribute to the disruption of the skin's structural integrity.
IL-17 inhibitors, such as secukinumab, ixekizumab, and brodalumab, have been developed to target and block the activity of IL-17A or its receptor (IL-17RA). These agents have demonstrated remarkable efficacy in clinical trials, providing rapid and substantial improvements in disease severity and skin clearance. By inhibiting IL-17A, these biologics disrupt the cytokine's ability to induce keratinocyte proliferation and inflammation, resulting in reduced psoriatic plaque formation.

4. Clinical efficacy of TNF-α and IL-17 Inhibitors
Biologic agents targeting TNF-α and IL-17 have been extensively studied in clinical trials, with several agents receiving approval for the treatment of moderate to severe psoriasis. The efficacy of these biologics is typically measured through endpoints such as the Psoriasis Area and Severity Index (PASI), which quantifies the percentage improvement in skin lesions. PASI 75, PASI 90, and PASI 100 represent 75%, 90%, and 100% improvement in skin lesions, respectively. These endpoints, along with patient-reported outcomes, provide a comprehensive assessment of the clinical benefits of biologic therapies.

4.1 TNF-α Inhibitors
- **Infliximab**: Infliximab is a chimeric monoclonal antibody that binds to TNF-α, neutralizing its biological activity. It has demonstrated rapid efficacy in clinical trials, with approximately 80% of patients achieving PASI 75 within 10 weeks of treatment. Infliximab is typically administered via intravenous infusion, and its rapid onset of action makes it particularly useful for patients with severe or refractory psoriasis.
- **Etanercept**: Etanercept is a fusion protein that acts as a decoy receptor for TNF-α, preventing the cytokine from binding to its cellular receptors. Clinical studies have shown that etanercept can achieve PASI 75 in 50-70% of patients after 12 weeks of therapy. It is administered via subcutaneous injection and is generally well-tolerated, making it a popular choice for long-term management.
- **Adalimumab**: Adalimumab is a fully human monoclonal antibody that specifically targets TNF-α. It has been shown to provide sustained efficacy, with 70-80% of patients achieving PASI 75 by week 16. Adalimumab is administered subcutaneously and has demonstrated long-term safety and efficacy in treating psoriasis.

TNF-α Inhibitors	PASI 75 (%)	PASI 90 (%)	PASI 100 (%)	Time to Response	Administration
Infliximab	~80%	~50%	~25%	10 weeks	Intravenous
Etanercept	50-70%	~40%	~20%	12 weeks	Subcutaneous
Adalimumab	70-80%	~50%	~30%	16 weeks	Subcutaneous

4.2 IL-17 Inhibitors
- **Secukinumab**: Secukinumab is a fully human monoclonal antibody that targets IL-17A. It has achieved remarkable efficacy, with nearly 70% of patients attaining PASI 90 within 12 weeks of treatment. Secukinumab is administered via subcutaneous injection and has become one of the most effective therapies for moderate to severe psoriasis.
- **Ixekizumab**: Ixekizumab is another IL-17A inhibitor with similar efficacy to secukinumab. Clinical trials have shown that ixekizumab can achieve PASI 100 in a significant proportion of patients by week 12, making it a highly effective treatment option.
- **Brodalumab**: Brodalumab targets the IL-17 receptor A (IL-17RA), blocking the signaling pathway of IL-17A, IL-17F, and other IL-17 family cytokines. It has demonstrated rapid efficacy, with 35-40% of patients achieving PASI 100 by week 16. Brodalumab offers an alternative mechanism of IL-17 inhibition, providing robust results for patients with challenging disease.

IL-17 Inhibitors	PASI 75 (%)	PASI 90 (%)	PASI 100 (%)	Time to Response	Administration
Secukinumab	~90%	~70%	~40%	12 weeks	Subcutaneous
Ixekizumab	~85%	~65%	~50%	12 weeks	Subcutaneous
Brodalumab	~85%	~70%	~35%	16 weeks	Subcutaneous

4.3 Comparison of TNF-α and IL-17 Inhibitors
When comparing TNF-α and IL-17 inhibitors, IL-17 inhibitors tend to demonstrate superior efficacy, particularly in achieving PASI 90 and PASI 100 endpoints. IL-17 inhibitors also have a faster onset of action and are more likely to result in complete or near-complete skin clearance. However, TNF-α inhibitors have been in use for a longer period, providing more robust long-term safety data. Both classes of biologics are generally well-tolerated, but careful patient selection and monitoring are essential to minimize the risk of infections and other adverse effects.

5. Comparative efficacy and safety profiles
The therapeutic targeting of TNF-α and IL-17 has transformed the management of moderate to severe psoriasis. Both classes of biologic agents offer substantial improvements in clinical outcomes compared to traditional systemic therapies. However, when comparing TNF-α and IL-17 inhibitors, differences in their efficacy profiles, speed of action, and safety concerns become evident, making this comparison crucial for clinicians when tailoring treatment strategies for individual patients.

5.1 Efficacy Comparison
IL-17 inhibitors, including secukinumab, ixekizumab, and brodalumab, have demonstrated superior efficacy in achieving higher PASI responses (PASI 90 and PASI 100) compared to TNF-α inhibitors such as infliximab, etanercept, and adalimumab. This is particularly important because achieving higher PASI scores correlates with greater disease control, improved quality of life, and long-term remission.

Several head-to-head clinical trials and real-world studies have confirmed that IL-17 inhibitors offer faster and more complete skin clearance than TNF-α inhibitors. In particular, IL-17 inhibitors are more likely to achieve PASI 90 or PASI 100 (complete or near-complete skin clearance) within 12-16 weeks of treatment initiation, whereas TNF-α inhibitors typically result in slower and less complete responses.

Biologic Class	PASI 75 (%)	PASI 90 (%)	PASI 100 (%)	Time to PASI 90 Response
TNF-α Inhibitors	70-80%	50-60%	20-30%	12-16 weeks
IL-17 Inhibitors	85-90%	70-75%	40-50%	8-12 weeks

For example, in clinical trials, secukinumab (an IL-17 inhibitor) has shown PASI 90 rates as high as 70% within 12 weeks, whereas TNF-α inhibitors such as adalimumab typically achieve PASI 90 in about 50-60% of patients over the same period. Additionally, IL-17 inhibitors are more likely to maintain these high levels of disease control with fewer treatment failures or relapses.

5.2 Speed of Onset
IL-17 inhibitors generally provide faster clinical responses compared to TNF-α inhibitors. This rapid onset of action is particularly beneficial for patients with severe or rapidly progressing psoriasis. Patients on IL-17 inhibitors, such as ixekizumab, often experience significant improvements in PASI scores within the first 2-4 weeks of treatment, with many achieving near-complete skin clearance (PASI 100) by 12 weeks.

In contrast, TNF-α inhibitors, while effective, tend to have a slower onset of action. Infliximab, due to its intravenous administration, may provide relatively faster results compared to subcutaneous TNF-α inhibitors like etanercept, but IL-17 inhibitors still outperform TNF-α inhibitors in terms of speed and magnitude of response.

5.3 Safety Profiles
TNF-α Inhibitors: TNF-α inhibitors have been used in clinical practice for over two decades, providing substantial long-term safety data. However, their use is associated with specific safety concerns, particularly related to infections. TNF-α plays a role in the body's defense against infections, and blocking TNF-α can lead to an increased risk of serious infections, including tuberculosis (TB), fungal infections, and reactivation of latent viral infections such as hepatitis B. For this reason, patients on TNF-α inhibitors are typically screened for latent TB before initiating treatment.

Additionally, TNF-α inhibitors have been associated with other adverse effects, such as congestive heart failure exacerbation, demyelinating diseases (e.g., multiple sclerosis), and malignancies (e.g., non-melanoma skin cancers). However, these risks are generally low, and TNF-α inhibitors remain a viable option for many patients, particularly those with comorbid conditions such as psoriatic arthritis.

IL-17 Inhibitors: IL-17 inhibitors have a different safety profile compared to TNF-α inhibitors, although they are associated with their own unique risks. One of the major concerns with IL-17 inhibition is the potential exacerbation of inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis. IL-17 plays a protective role in maintaining gut homeostasis, and blocking IL-17 may lead to new onset or worsening of IBD in susceptible individuals.

While infections are also a concern with IL-17 inhibitors, the risk of serious infections, including TB, appears to be lower compared to TNF-α inhibitors. Nevertheless, patients on IL-17 inhibitors should still be monitored for signs of infection, and appropriate screening measures should be in place.

Safety Profile	TNF-α Inhibitors	IL-17 Inhibitors
Infection Risk	Increased risk of serious infections (e.g., TB, fungal)	Lower risk of infections compared to TNF-α inhibitors
Tuberculosis Reactivation	Common concern, requires TB screening	Lower risk, but screening still recommended
Inflammatory Bowel Disease	No exacerbation	Potential worsening or new onset of IBD
Other Risks	Heart failure exacerbation, demyelinating diseases, malignancy (low risk)	Exacerbation of pre-existing IBD, rare candidiasis

5.4 Long-Term Use and Patient Adherence

TNF-α inhibitors have a longer history of use in clinical practice, and extensive long-term safety and efficacy data are available. Patients treated with TNF-α inhibitors may require regular monitoring for adverse effects such as infections or malignancies, but these agents are generally well-tolerated in the long term.

IL-17 inhibitors, being newer to the market, have relatively less long-term safety data available. However, early indications suggest that they offer sustained efficacy and safety over time. Additionally, IL-17 inhibitors may have higher patient adherence rates due to their faster onset of action and better skin clearance, which can improve patient satisfaction and quality of life.

6. Conclusion

The therapeutic targeting of TNF-α and IL-17 has revolutionized the treatment landscape for moderate to severe psoriasis. Both classes of biologic agents have proven highly effective in controlling the inflammatory processes that underlie psoriasis, providing significant improvements in clinical outcomes and quality of life for patients. TNF-α inhibitors, with their long-standing use, offer a well-established safety profile and efficacy in both psoriasis and psoriatic arthritis. On the other hand, IL-17 inhibitors, which represent a newer generation of biologics, have demonstrated superior efficacy in achieving higher levels of skin clearance, particularly in terms of PASI 90 and PASI 100 responses. Their faster onset of action and ability to deliver near-complete skin clearance make them a preferred option for many patients.

Despite their efficacy, both TNF-α and IL-17 inhibitors carry specific safety risks. TNF-α inhibitors are associated with an increased risk of serious infections, such as tuberculosis, while IL-17 inhibitors have been linked to exacerbation of inflammatory bowel disease. The choice between these biologic therapies should be carefully considered based on individual patient profiles, including comorbid conditions and previous treatment responses. Long-term data on the safety of IL-17 inhibitors are still emerging, and ongoing monitoring will be critical to fully understanding their risk-benefit profile in chronic use.

Looking ahead, continued advancements in biologic therapies, including the development of biosimilars and combination treatment strategies, are expected to further improve outcomes for psoriasis patients. Research into the long-term safety of IL-17 inhibitors, optimized dosing regimens, and the potential for personalized medicine based on patient-specific biomarkers will help tailor treatments to individual needs, improving both efficacy and safety. The future of psoriasis management will likely see more personalized and integrative approaches that combine biologic therapies with other modalities to achieve durable disease control with minimal adverse effects. Overall, the targeting of TNF-α and IL-17 represents a critical milestone in the quest for more effective, safe, and patient-centered treatments for psoriasis.

7. References

1. Blauvelt A, Reich K, Tsai TF, Tyring S, Vanaclocha F, Kingo K, *et al*. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2017;76(1):60-69. https://doi.org/10.1016/j.jaad.2016.08.008
2. Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, *et al*. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318-1328. https://doi.org/10.1056/NEJMoa1503824
3. Reich K, Papp KA, Blauvelt A, Tyring S, Sinclair R, Thaci D, *et al*. A randomized phase 3 trial of secukinumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2015;373(15):1447-1458. https://doi.org/10.1056/NEJMoa1414263
4. Gisondi P, Geat D, Girolomoni G. Biologic therapies and the risk of infections in psoriasis. G Ital Dermatol Venereol. 2020;155(1):1-10. https://doi.org/10.23736/S0392-0488.19.06447-9
5. Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, *et al*. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345-356. https://doi.org/10.1056/NEJMoa1512711
6. Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Popov MV, *et al*. Efficacy and safety of ustekinumab, with and without concomitant methotrexate, in patients with active psoriatic arthritis: Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2013;65(12):3294-3303. https://doi.org/10.1002/art.38123
7. Armstrong AW, Schupp CW, Wu J, Bebo BF. Quality of life and work productivity impairment among psoriasis patients: Findings from the National Psoriasis Foundation Survey Data 2003–2011. PLoS One. 2017;7(12):e52935. https://doi.org/10.1371/journal.pone.0052935
8. Gisondi P, Geat D, Girolomoni G. Impact of IL-17 inhibitors on quality of life of patients with moderate-to-severe psoriasis: A systematic review and meta-analysis. Clin Cosmet Investig Dermatol. 2021;14:661-671. https://doi.org/10.2147/CCID.S312234
9. Gooderham M, Papp KA, Lynde C, Gladman DD. Managing patients with psoriatic disease: The impact of biologics on comorbidities and quality of life. J Cutaneous Med Surg. 2018;22(5):493-505. https://doi.org/10.1177/1203475418783025
10. Lebwohl MG, Kavanaugh A, Armstrong AW, Van Voorhees AS. US perspectives in the management of psoriasis and psoriatic arthritis: Patient and physician results from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Am J Clin Dermatol. 2014;15(2):209-215. https://doi.org/10.1007/s40257-014-0060-y
11. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J Investig Dermatol. 2013;133(2):377-385. https://doi.org/10.1038/jid.2012.339
12. Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983-994. https://doi.org/10.1016/S0140-6736(14)61909-7
13. Lowes MA, Suarez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227-255. https://doi.org/10.1146/annurev-immunol-032713-120225

14. Gisondi P, Altomare G, Ayala F, Conti A, Dapavo P, De Simone C, *et al*. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31(5):774-790. https://doi.org/10.1111/jdv.14144
15. Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014;74(4):423-441. https://doi.org/10.1007/s40265-014-0191-2
16. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, *et al*. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371(4):326-338. https://doi.org/10.1056/NEJMoa1314258
17. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496-509. https://doi.org/10.1056/NEJMra0804595
18. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, *et al*. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-850. https://doi.org/10.1016/j.jaad.2008.02.039
19. Guttman-Yassky E, Krueger JG, Lebwohl MG. Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment. J Allergy Clin Immunol. 2017;140(3):645-653. https://doi.org/10.1016/j.jaci.2017.07.004
20. Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, *et al*. Efficacy and safety of guselkumab, an interleukin-23–specific monoclonal antibody, compared with adalimumab for the treatment of moderate to severe psoriasis: Results from the phase III VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405-417. https://doi.org/10.1016/j.jaad.2016.11.041
21. Reich K, Papp KA, Blauvelt A, Tyring S, Sinclair R, Thaci D, *et al*. A randomized phase 3 trial of secukinumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2015;373(15):1447-1458. https://doi.org/10.1056/NEJMoa1414263
22. Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, *et al*. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345-356. https://doi.org/10.1056/NEJMoa1512711